MADCAM1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue lysate, Primary antibody: P11011(MADCAM1 Antibody) at dilution 1/1150, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11011(MADCAM1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

MAdCAM-1 (Mucosal Vascular Addressin Cell Adhesion Molecule 1) is a cell surface glycoprotein primarily expressed on endothelial cells in mucosal tissues, gut-associated lymphoid organs, and inflamed sites. It belongs to the immunoglobulin superfamily and plays a critical role in lymphocyte trafficking to mucosal regions by binding to integrin α4β7 and L-selectin on leukocytes. This interaction facilitates the selective homing of immune cells, particularly lymphocytes, to intestinal and gut-associated lymphoid tissues, making MAdCAM-1 a key mediator in mucosal immunity and inflammation.

MAdCAM-1 antibodies are therapeutic or experimental tools designed to block this adhesion pathway. In inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, MAdCAM-1 is overexpressed, promoting excessive leukocyte infiltration and tissue damage. Anti-MAdCAM-1 antibodies (e.g., ontamalimab) aim to inhibit integrin binding, thereby reducing inflammation. Preclinical and clinical studies highlight their potential to suppress chronic inflammation while preserving systemic immunity, offering a targeted approach compared to broader immunosuppressants. Research also explores their role in autoimmune disorders and cancer immunotherapy. Despite promise, challenges include optimizing specificity and managing long-term safety profiles. Overall, MAdCAM-1 antibodies represent a biologically rational strategy for modulating gut-specific immune responses.